Table 3 The AGREE II Instrument
From: Systematic review of guideline-recommended medications prescribed for treatment of low back pain
| AGREE II domains and items | |
|---|---|
| Domain 1. Scope and Purpose | |
| 1. The overall objective(s) of the guideline is (are) specifically described | |
| 2. The health question(s) covered by the guideline is (are) specifically described | |
| 3. The population (patients, public, etc.) to whom the guideline is meant to apply is specifically described | |
| Domain 2. Stakeholder Involvement | |
| 4. The guideline development group includes individuals from all relevant professional groups | |
| 5. The views and preferences of the target population (patients, public, etc.) have been sought | |
| 6. The target users of the guideline are clearly defined | |
| Domain 3. Rigor of Development | |
| 7. Systematic methods were used to search for evidence | |
| 8. The criteria for selecting the evidence are clearly described | |
| 9. The strengths and limitations of the body of evidence are clearly described | |
| 10. The methods for formulating the recommendations are clearly described | |
| 11. The health benefits, side effects, and risks have been considered in formulating the recommendations | |
| 12. There is an explicit link between the recommendations and the supporting evidence | |
| 13. The guideline has been externally reviewed by experts prior to its publication | |
| 14. A procedure for updating the guideline is provided | |
| Domain 4. Clarity of Presentation | |
| 15. The recommendations are specific and unambiguous | |
| 16. The different options for management of the condition or health issue are clearly presented | |
| 17. Key recommendations are easily identifiable | |
| Domain 5. Applicability | |
| 18. The guideline describes facilitators and barriers to its application | |
| 19. The guideline provides advice and/or tools on how the recommendations can be put into practice | |
| 20. The potential resource implications of applying the recommendations have been considered | |
| 21. The guideline presents monitoring and/or auditing criteria | |
| Domain 6. Ethical Independence | |
| 22. The views of the funding body have not influenced the content of the guideline | |
| 23. Competing interests of guideline development group members have been recorded and addressed |